Array Biopharma Inc (NASDAQ:ARRY) currently trades at $10.61 which is about -5.18% lower than the 52-week high of $11.65. The trading volume at ready counter moved to 5.25M shares as compared to 4.10M shares average traded volume. The stock failed to get pushed above the $10.84 barrier, the intraday high, after opening at $10.77. Analysts have a consensus target price of $10.13 in the 12-month period. Its market capitalization has now reached to $1.81B.
Array Biopharma Inc (NASDAQ:ARRY) was dropped to Underweight from Equal Weight at Barclays. It has earned a consensus Strong buy rating, according to Zacks Investment Research. No analyst has rated the stock with a sell rating, 0 have assigned a hold rating, Zero says it’s a buy and 9 have assigned a strong buy rating to the company.
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The companys drugs in Phase III clinical trials include Binimetinib, Encorafenib, and Selumetinib for the treatment of cancer, as well as ASC08/Danoprevir, a protease inhibitor for hepatitis C virus. Its drug candidates in Phase II clinical trials comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy; ASLAN001/Varlitinib, a pan-HER2 inhibitor for gastric or breast cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; Motolimod/VTX-2337, a toll-like receptor for cancer; Prexasertib/LY2606368, a chk-1 inhibitor for cancer; LOXO-101, a PanTrk inhibitor for cancer; and ONT-380/ARRY-380, an HER2 inhibitor for breast cancer. The companys Phase I drugs include GDC-0994, an ERK inhibitor for cancer; and ARRY-382, a CSF1R inhibitor for cancer, as well as Phase Ib drug candidate comprises GDC-0575, a chk-1 inhibitor for cancer. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.